Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Henry Schein's Quarterly Earnings Preview: What You Need to Know

Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, as well as alternative sites of care worldwide. With a market capitalization of $8.6 billion, the company operates through four segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology.

HSIC is all geared up to report its Q2 2025 results on Tuesday, August 5. Before this event, analysts project that the company will report an adjusted EPS of $1.19, down 3.3% from $1.23 in the year-ago quarter. The company has surpassed or matched Wall Street's bottom-line estimates in each of the last four quarters, which is impressive. 

 

For fiscal 2025, analysts expect HSIC to report an adjusted EPS of $4.86, representing a 2.5% year-over-year increase from $4.74 in fiscal 2024. Moreover, in fiscal 2026, the company’s adjusted EPS is expected to increase 8.6% year-over-year to $5.28. 

www.barchart.com 

HSIC stock has grown 7.3% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 10.9% gain but outperforming the Health Care Select Sector SPDR Fund’s (XLV) 10.3% decline over the same time frame.

www.barchart.com 

HSIC stock rose 2% following the release of its Q1 2025 results on May 5. The company’s net sales declined marginally year-over-year to $3.2 billion, missing the consensus estimate. Meanwhile, its adjusted EPS grew 4.5% from the prior-year quarter to $1.15, surpassing analysts’ estimate by 3.6%.

Analysts are moderately optimistic about HISC’s stock, with an overall "Moderate Buy" rating. Among 14 analysts covering the stock, five recommend "Strong Buy," eight advise “Hold,” and one suggests “Strong Sell.” The mean price target of $77 indicates a 9% potential upside from HSIC’s current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.